Floatz logo

2,4-PYRIMIDINEDIAMINE, N(SUP 4)-(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)-N(SUP 2)-((3-(1-METHYLETHYL)-5-ISOXAZOLYL)METHYL)-6-(4-METHYL-1-PIPERAZINYL)-

Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

ExelixisSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

35 Active assets in the Leukemia, Lymphoblastic, Acute, Philadelphia-Positive cohort.

Asset / SponsorPhaseRating
Nilotinib
The University of Hong Kong
Phase 2BBB
Blinatumomab
Novartis Pharmaceuticals
Phase 3BBB
Cytosin-Arabinosid
Novartis Pharmaceuticals
Phase 3BBB
METHOTREXATE
Novartis Pharmaceuticals
Phase 3BB
Imatinib
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

2,4-PYRIMIDINEDIAMINE, N(SUP 4)-(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)-N(SUP 2)-((3-(1-METHYLETHYL)-5-ISOXAZOLYL)METHYL)-6-(4-METHYL-1-PIPERAZINYL)- is also rated in:

chronic myeloid leukemiaDormant
CC
Indicative ·
41 / 100
View asset →
cancerDormant
C
Indicative ·
37 / 100
View asset →
lymphomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →